Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Cancer Treat Rev. 2022 Nov;110:102462. doi: 10.1016/j.ctrv.2022.102462. Epub 2022 Sep 6.
Metastatic breast cancer represents an incurable condition, however, the increasing interest towards the oligometastatic entity is now challenging this assumption. Up to 20% of patients with metastatic breast cancer present with oligometastatic disease, which refers to metastatic breast cancer presenting or recurring with limited metastatic burden. In the last years, progressive advancements in imaging techniques, the growing availability of minimally invasive locoregional treatments, alongside the increasing expectations from a patient perspective, have contributed to rising the awareness towards this emerging entity. In the present work we comprehensively reviewed available evidence regarding oligometastatic breast cancer, focusing on clinical and biological notions virtually supporting the adoption of a curative approach when treating this condition. We also discussed main areas of uncertainties, providing a research agenda that may guide and fine-tune the future investigation in this field.
转移性乳腺癌是一种不可治愈的疾病，但人们对寡转移实体的日益关注现在正在挑战这一假设。高达 20%的转移性乳腺癌患者存在寡转移疾病，这是指转移性乳腺癌出现或复发时转移负担有限。在过去几年中，成像技术的不断进步、微创局部治疗手段的日益普及，以及患者期望的不断提高，都促使人们对这一新兴实体的认识不断提高。在本工作中，我们全面回顾了关于寡转移乳腺癌的现有证据，重点关注了支持在治疗这种疾病时采用治愈方法的临床和生物学概念。我们还讨论了主要的不确定性领域，提供了一个研究议程，可能指导和微调这一领域的未来研究。
